2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse eventsEvaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2023
Wireless technologies, non-ionizing electromagnetic fields and children: Identifying and reducing health risks
Davis D, Birnbaum L, Ben-Ishai P, Taylor H, Sears M, Butler T, Scarato T. Wireless technologies, non-ionizing electromagnetic fields and children: Identifying and reducing health risks. Current Problems In Pediatric And Adolescent Health Care 2023, 53: 101374. PMID: 36935315, DOI: 10.1016/j.cppeds.2023.101374.Peer-Reviewed Original Research
2021
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemicEndometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling
Chen P, Mamillapalli R, Habata S, Taylor HS. Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling. Molecular And Cellular Biochemistry 2021, 476: 1717-1727. PMID: 33428059, DOI: 10.1007/s11010-020-04012-1.Peer-Reviewed Original ResearchConceptsPD-1 expressionPD-1Stromal cellsT-cell PD-1 expressionEndometriosis stromal cellsGrowth of endometriosisPD-1 inductionDifferentiation of BMDCsBone marrow mesenchymal stem cell differentiationT cell quiescenceBMDC differentiationImmune toleranceEndometriosis patientsEndometriotic lesionsNormal endometriumEndometrial cellsEndometriosis cellsGynecological disordersImmune surveillanceMurine modelBMDCsEndometriosisLesion sizeCXCR4 receptorLesions
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherenceTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility And Sterility 2020, 114: 44-55. PMID: 32505383, DOI: 10.1016/j.fertnstert.2020.02.114.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painBone mineral densityNon-menstrual pelvic painPelvic painDose-dependent fashionSerum estradiolOral gonadotropin-releasing hormone antagonistSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOverall pelvic painRates of amenorrheaDose-ranging trialRandomized clinical trialsNumber of respondersPrimary endpointBMD lossTotal hipFemoral neckHormone antagonistClinical centersParallel groupClinical trialsMineral densityLife measuresMAIN OUTCOME
2019
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. American Journal Of Obstetrics And Gynecology 2019, 222: 592.e1-592.e10. PMID: 31759891, DOI: 10.1016/j.ajog.2019.11.1255.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painHealth-related qualityEndometriosis-associated painPelvic painMonth 3Clinical responseClinical respondersPain symptomsMeaningful improvementsEndometriosis-related pain symptomsSevere endometriosis-associated painSevere endometriosis-related painGonadotropin-releasing hormone antagonistPhase III clinical trialsPain reduction scoresPain responder statusSelf-reported bleedingPlacebo-controlled studyEndometriosis-related painSelf-reported painWork productivityReceiver-operating characteristic analysisNumber of symptomsProductivity QuestionnairePatterns of Prescription Opioid Use in Women With Endometriosis
Lamvu G, Soliman AM, Manthena SR, Gordon K, Knight J, Taylor HS. Patterns of Prescription Opioid Use in Women With Endometriosis. Obstetrics And Gynecology 2019, 133: 1120-1130. PMID: 31135725, PMCID: PMC6553518, DOI: 10.1097/aog.0000000000003267.Peer-Reviewed Original ResearchConceptsOpioid prescriptionsControl groupBenzodiazepine prescriptionsOpioid useEndometriosis patientsCase groupClinformatics DataMart databaseFirst opioid prescriptionMultiple opioid prescriptionsOpioid Prescribing PatternsPrescription opioid useMultivariable regression analysisRelative risk ratiosConcomitant opioidsPrescribing patternsDaily doseMean ageRisk ratioConcomitant useDays' supplyRetrospective analysisInsurance payerΧ statisticEndometriosisPatients
2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics And Gynecology 2018, 132: 147-160. PMID: 29889764, DOI: 10.1097/aog.0000000000002675.Peer-Reviewed Original ResearchConceptsMonths of treatmentResponder rateAdverse eventsPlacebo-controlled phase 3 trialGonadotropin-releasing hormone antagonistBone mineral density assessmentCoprimary efficacy endpointsEndometriosis-associated painNonmenstrual pelvic painPelvic pain scoresSafety of elagolixCommon adverse eventsPhase 3 trialProportion of respondersNew safety concernsBone mineral densityClinical laboratory testsElagolix dosesElagolix treatmentEndometrial findingsEfficacy endpointPain scoresPelvic painHot flushesTerm outcomesMajor depression, antidepressant use, and male and female fertility
Evans-Hoeker EA, Eisenberg E, Diamond MP, Legro RS, Alvero R, Coutifaris C, Casson PR, Christman GM, Hansen KR, Zhang H, Santoro N, Steiner AZ, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Ager J, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Lecks K, Martino L, Marunich R, Comfort A, Crow M, Hohmann A, Mallette S, Smith Y, Randolph J, Fisseha S, Ohl D, Ringbloom M, Tang J, Bates W, Mason S, Craig L, Zornes C, Rodriguez M, Hunt T, DiMaria N, Usadi R, Lucidi S, Rhea M, Baker V, Turner K, Brennan M, DelBasso D, Huang H, Jin Y, Li Y, Kuang H, Makuch R, Patrizio P, Sakai L, Scahill L, Song C, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Trussell J, Laylor B, Martinez L, Solnica A, Wojtczuk A, Seungdamrong A, Rosen M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Major depression, antidepressant use, and male and female fertility. Fertility And Sterility 2018, 109: 879-887. PMID: 29778387, PMCID: PMC5973807, DOI: 10.1016/j.fertnstert.2018.01.029.Peer-Reviewed Original ResearchConceptsMaternal major depressionMaternal antidepressant useAntidepressant useLikelihood of pregnancyMale partnersMajor depressionNon-IVF fertility treatmentsFirst trimester pregnancy lossTypes of antidepressantsPHQ-9 scoresFirst trimester miscarriagePatient Health QuestionnairePoor fertility outcomesRisk of miscarriagePoisson regression modelsPPCOS IICohort studyPregnancy outcomesMedication usePrimary outcomeRandomized trialsPregnancy lossHealth QuestionnaireRelative riskTreatment outcomes
2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushesIncremental direct and indirect cost burden attributed to endometriosis surgeries in the United States
Soliman AM, Taylor H, Bonafede M, Nelson JK, Castelli-Haley J. Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States. Fertility And Sterility 2017, 107: 1181-1190.e2. PMID: 28476181, DOI: 10.1016/j.fertnstert.2017.03.020.Peer-Reviewed Original ResearchConceptsPost-index periodEndometriosis patientsSurgery cohortIndirect costsDirect costsHigher healthcare resource utilizationTruven Health MarketScan CommercialIndirect cost burdenProductivity Management databasesRetrospective cohort studyHealthcare resource utilizationAnnual indirect costsShort-term disabilityAnnual direct costsTotal healthcare expendituresHigher direct costsTotal indirect costsEndometriosis surgeryIndex surgeryCohort studyMarketScan CommercialPrimary outcomeSurgery typeHealthcare utilizationMAIN OUTCOMERacial and ethnic differences in the polycystic ovary syndrome metabolic phenotype
Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, Coutifaris C, Diamond MP, Eisenberg E, Zhang H, Santoro N, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. American Journal Of Obstetrics And Gynecology 2017, 216: 493.e1-493.e13. PMID: 28104402, PMCID: PMC5420474, DOI: 10.1016/j.ajog.2017.01.003.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeNon-Hispanic black womenNon-Hispanic whitesOvarian syndromeMetabolic syndromeNon-Hispanic blacksHispanic womenInsulin resistanceCardiovascular diseaseHigh prevalenceEthnic differencesType 2 diabetes mellitusLower serum triglyceride levelsNon-Hispanic white womenLower sex hormonePrevalence of hypertriglyceridemiaFree androgen indexHomeostasis model assessmentPolycystic ovary syndromeBody mass indexMetabolic phenotypeSerum triglyceride levelsType 2 diabetesBlack womenAndrogen index
2015
Predictors of participant retention in infertility treatment trials
Kuang H, Jin S, Thomas T, Engmann L, Hansen KR, Coutifaris C, Casson P, Christman G, Alvero R, Santoro N, Eisenberg E, Diamond MP, Legro RS, Zhang H, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Easton C, Hernandez A, Leija M, Pierce D, Bryzski R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Lecks K, Martino L, Marunich R, Snyder P, Schlaff W, Comfort A, Crow M, Hohmann A, Mallette S, Ringbloom M, Tang J, Mason S, DiMaria N, Rhea M, Turner K, Haisenleder D, Trussell J, DelBasso D, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Zhang M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Predictors of participant retention in infertility treatment trials. Fertility And Sterility 2015, 104: 1236-1243.e2. PMID: 26354094, PMCID: PMC4630082, DOI: 10.1016/j.fertnstert.2015.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChi-Square DistributionDrug Therapy, CombinationFemaleFertilityFertility Agents, FemaleHumansInfertility, FemaleLogistic ModelsMaleMultivariate AnalysisOdds RatioPatient DropoutsPatient SelectionPolycystic Ovary SyndromePregnancyRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeYoung AdultConceptsPolycystic ovary syndromeBody mass indexClomiphene citrateClinical trialsHistory of smokingInsurance coverageCombination of metforminMultivariable logistic modelAcademic medical centerRetention of subjectsConduct of RCTsBetter insurance coverageUnexplained infertilityOvary syndromeNormal weightMass indexOriginal RCTTreatment trialsMedical CenterMAIN OUTCOMEWhite raceIntervention studiesRCTsSecondary analysisParticipant retentionPeripheral Microvascular Vasodilatory Response to Estradiol and Genistein in Women with Insulin Resistance
Wenner MM, Taylor HS, Stachenfeld NS. Peripheral Microvascular Vasodilatory Response to Estradiol and Genistein in Women with Insulin Resistance. Microcirculation 2015, 22: 391-399. PMID: 25996650, PMCID: PMC4506724, DOI: 10.1111/micc.12208.Peer-Reviewed Original ResearchConceptsL-NMMAMicrovascular vasodilationHealthy womenVasodilatory responsivenessLocal cutaneous heatingMicrovascular vasodilatory functionMicrovascular vasodilatory responsesBeat blood pressureHealthy young womenLaser Doppler flowmetryHeat-induced vasodilationMicrovascular responsivenessVascular effectsVasodilatory responseBlood pressureMicrovascular functionVasodilatory functionCutaneous heatingInsulin resistanceCutaneous circulationDoppler flowmetryGEN exposureInteraction of E2VasodilationMicrodialysis perfusionCirculating microRNAs as potential biomarkers for endometriosis
Cho S, Mutlu L, Grechukhina O, Taylor HS. Circulating microRNAs as potential biomarkers for endometriosis. Fertility And Sterility 2015, 103: 1252-1260.e1. PMID: 25772772, PMCID: PMC4417410, DOI: 10.1016/j.fertnstert.2015.02.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultArea Under CurveCase-Control StudiesCell ProliferationEndometriosisFemaleGenetic MarkersHospitals, UniversityHumansLogistic ModelsMicroRNAsMiddle AgedPredictive Value of TestsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionROC CurveYoung AdultConceptsProliferative phaseLet-7bSerum CA-125 levelsMiR-135aCA-125 levelsSerum of womenBenign gynecologic diseaseCase-control studyQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionPotential noninvasive biomarkersLogistic regression modelsHighest areaGynecologic diseasePolymerase chain reactionUniversity HospitalMenstrual cycleEndometriosisMAIN OUTCOMENoninvasive biomarkersPotential biomarkersDiagnostic markerSerum samplesWomenChain reaction
2012
Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
Resuehr D, Glore DR, Taylor HS, Bruner-Tran KL, Osteen KG. Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Fertility And Sterility 2012, 98: 948-956.e1. PMID: 22789143, PMCID: PMC3462249, DOI: 10.1016/j.fertnstert.2012.06.009.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsEndometrial tissueStromal cellsCannabinoid receptor type 1 expressionProgesterone-dominated secretory phaseMRNA expressionAnti-inflammatory actionMessenger RNATetrachlorodibenzo-p-dioxin (TCDD) exposureHuman endometrial tissueProgesterone receptor antagonistType 1 expressionSteroid-induced expressionProgesterone-dependent regulationEndometrial biopsyReceptor antagonistCannabinoid signalingHuman endometriumMedical CenterMAIN OUTCOMESecretory phaseControl donorsEndometriosisDifferentiation-related expressionExposure disruptsStatins Inhibit Monocyte Chemotactic Protein 1 Expression in Endometriosis
Cakmak H, Basar M, Seval-Celik Y, Osteen KG, Duleba AJ, Taylor HS, Lockwood CJ, Arici A. Statins Inhibit Monocyte Chemotactic Protein 1 Expression in Endometriosis. Reproductive Sciences 2012, 19: 572-579. PMID: 22267540, PMCID: PMC3439122, DOI: 10.1177/1933719111430998.Peer-Reviewed Original ResearchConceptsCultured endometriotic cellsMonocyte chemotactic protein-1 expressionChemotactic protein-1 expressionMCP-1 productionEndometriotic cellsProtein-1 expressionEndometriotic implantsMouse modelMCP-1 messenger RNA expressionExerts anti-inflammatory effectsAnti-inflammatory effectsEffect of statinsAnti-inflammatory propertiesMCP-1 expressionMevalonate pathwayDose-dependent inhibitionNude mouse modelMessenger RNA expressionDose-dependent mannerEctopic endometriumEndometrial cellsPeritoneal surfaceStatinsPotential treatmentInhibitory effectThe Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, Christman GM, Coutifaris C, Taylor HS, Eisenberg E, Santoro N, Zhang H, Network F. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemporary Clinical Trials 2012, 33: 470-481. PMID: 22265923, PMCID: PMC3312939, DOI: 10.1016/j.cct.2011.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsChi-Square DistributionClomipheneDouble-Blind MethodFemaleFertility Agents, FemaleHealth Status IndicatorsHirsutismHumansHyperandrogenismInfertility, FemaleLetrozoleMiddle AgedNitrilesOvulation InductionPolycystic Ovary SyndromePregnancyQuality of LifeResearch DesignTriazolesWomen's HealthYoung AdultConceptsPolycystic ovary syndromeClomiphene citrateOvary syndromeInfertile womenTreatment armsDouble-blind clinical trialSelective estrogen receptor modulatorsMajor infertility factorOral clomiphene citrateMultiple pregnancy rateFirst-line treatmentLive birth rateEstrogen receptor modulatorsDifferent treatment armsTreatment of infertilityPoor ovulatory responseEndometrial effectsII trialII studyLine treatmentInfertility factorsProgestin withdrawalAromatase inhibitorsClinical trialsFemale infertility
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply